Camurus AB
Research Camurus AB (0RD1) with Bullrun company financials, valuation charts, model signals, and historical stock context.
Key Metrics
- Ticker0RD1
- ExchangeLSE
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencySEK
- Financial periodQ4 2025
- RevenueSEK 464.46M
- Net incomeSEK 100.88M
- Free cash flowSEK 209.64M
- Gross margin92.2%
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-11 | n/a | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 SEK.
About Camurus AB
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain;
Related stock research
Other Healthcare stocks
Frequently asked questions
What does Camurus AB do?
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder.